Skip to main content
. Author manuscript; available in PMC: 2010 Dec 14.
Published in final edited form as: Cancer Res. 2010 Jun 1;70(12):4891–4900. doi: 10.1158/0008-5472.CAN-09-4319

Fig. 3. All kinase-domain-localized MVA mutations affect overall BUBR1 protein abundance.

Fig. 3

(A) Northern blot of mRNA isolated from immortalized MVA lymphoblastoid (left) and fibroblast (right) cell lines. Band intensity of BUBR1/Tubulin relative to healthy control cells is shown (representative of 2 experiments). (B) Quantitative immunoblot of lysates of immortalized MVA lymphoblastoid cell lines. Band intensity of BUBR1/Tubulin of cells treated cells with cycloheximide for 5 hours relative to untreated cells is shown (average of 3 experiments). (C) Quantitative immunoblot of lysates of U2OS cells stably expressing wild-type or mutant LAP-BUBR1 together with BUBR1 shRNA, treated with DMSO (−), cycloheximide (CHX), geldanamycin (GA), MG132 (MG) or combinations for 5 hours (representative experiment is shown).